Market Place
Sourcing Support
Helsinn Group launches Akynzeo injection in US market
26 Jun 2024 //
PHARMABIZ
Helsinn`s AKYNZEO® Injection Now Available in Ready-to-Use Vial in the US
24 Jun 2024 //
GLOBENEWSWIRE
Helsinn and Angelini Pharma renew distribution deal
28 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Helsinn Angelini Aulin® Mesulid®: Partnership Renewal In Select Countries
27 May 2024 //
GLOBENEWSWIRE
Helsinn closes financing agreement with BancaStato
10 Oct 2023 //
GLOBENEWSWIRE
Helsinn announces publication of data evaluating impact of AKYNZEO
12 Jun 2023 //
GLOBENEWSWIRE
Helsinn announces publication of data evaluating impact of NEPA
03 Feb 2023 //
GLOBENEWSWIRE
Helsinn closes financing agreement with Oberland Capital
10 Jan 2023 //
GLOBENEWSWIRE
Helsinn announces the appointment of Dr Melanie Rolli as Group CEO
09 Jan 2023 //
GLOBENEWSWIRE
Helsinn publishes data evaluating chlormethine gel’s mode of action
18 Oct 2022 //
GLOBENEWSWIRE
BridgeBio says it`s undeterred after Truseltiq partner withdraws application
14 Oct 2022 //
FIERCEPHARMA
Helsinn presents newly available data on vepafestinib at IASLC 2022
08 Aug 2022 //
GLOBENEWSWIRE
New data on Helsinn`s oncology pipeline presented at ASCO 2022
02 Jun 2022 //
GLOBENEWSWIRE
Helsinn Establishes New R&D Hub in the U.S. to Support its FITT Strategy
25 May 2022 //
GLOBENEWSWIRE
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
19 May 2022 //
GLOBENEWSWIRE
Helsinn to present data at upcoming AMMF`s 2022 ECC
11 May 2022 //
GLOBENEWSWIRE
Juniper Biologics signs excl license agreement with Helsinn for infigratinib
04 May 2022 //
PRNEWSWIRE
After 25 years, Hovione`s CEO will step down; Helsinn gains infigratinib license
03 Mar 2022 //
ENDPTS
AnaCardio exercises option to license a program in heart failure from HelsinnE
03 Feb 2022 //
GLOBENEWSWIRE
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review
21 Dec 2021 //
GLOBENEWSWIRE
Helsinn and Xediton sign exclusive license and distribution agreement TRUSELTIQ
20 Dec 2021 //
GLOBENEWSWIRE
Helsinn announces EU Commission approval of the liquid formulation of AKYNZEO®
02 Dec 2021 //
GLOBENEWSWIRE
BridgeBio, Helsinn expand collaboration to cover cancer assets
20 Nov 2021 //
FIERCEBIOTECH
Inhibrx shares rise on PhI trial results; Braglia`s Helsinn partners with Fosun
12 Oct 2021 //
ENDPTS
Helsinn and Fosun Pharma sign exclusive license and distribution agreements
12 Oct 2021 //
GLOBENEWSWIRE
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care
24 Jun 2021 //
GLOBENEWSWIRE
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP)
13 Apr 2021 //
GLOBENEWSWIRE
Helsinn announces publication of latest mechlorethamine gel research
18 Feb 2021 //
GLOBENEWSWIRE
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06
12 Jan 2021 //
PRESS RELEASE
Helsinn to present two posters at the San Antonio Breast Cancer (SABCS)
07 Dec 2020 //
GLOBENEWSWIRE
Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and agreement
01 Dec 2020 //
GLOBENEWSWIRE
Helsinn Group and Italfarmaco announces oral presentation of NEPA data
18 Sep 2020 //
PRESS RELEASE
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution
20 Aug 2020 //
GLOBENEWSWIRE
MEI Pharma, Helsinn cut losses, ditch ph 3 partnered test for pracinostat
02 Jul 2020 //
FIERCE BIOTECH
Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts
10 Jun 2020 //
GLOBENEWSWIRE
Helsinn announces launch of oral formulation of Akynzeo® in China
08 Jun 2020 //
GLOBENEWSWIRE
Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 StudY
13 May 2020 //
PRNEWSWIRE
Quench Bio emerges with $50M to treat inflammatory diseases
27 Jan 2020 //
PR NEWSWIRE
Helsinn, MEI Pharma Publish Ph II Data for Pracinostat+Azacitidine
15 Feb 2019 //
GLOBENEWSWIRE
US top court rejects Helsinn over anti-nausea drug patent in win for Teva
23 Jan 2019 //
REUTERS
Aloxi (palonosetron hydrochloride): Helsinn Healthcare vs. Baxter Healthcare
24 Nov 2018 //
PATENT LITIGATION
Glenmark launches Helsinn`s Akynzeo in India
11 Jul 2018 //
BIOSPECTRUM
Glenmark expands its oncology franchise in India with launch of Akynzeo
11 Jul 2018 //
ECONOMIC TIMES
Glenmark launches FDC drug Akynzeo for chemotherapy-induced nausea and vomiting
10 Jul 2018 //
PHARMABIZ
Helsinn gives up on Zealand’s GI candidate elsiglutide after trial flop
12 Jun 2017 //
FIERCE BIOTECH
Mundipharma expands oncology portfolio
16 Feb 2017 //
BIOSPECTRUM
Helsinn receives USFDA marketing nod for Xonrid gel
05 Dec 2016 //
PHARMABIZ
USFDA Approves Soliqua 100/33 for the Treatment of Adults with Type 2 Diabetes
22 Nov 2016 //
GLOBENEWSWIRE
CHMP issues positive opinion recommending Suliqua for approval in the EU
11 Nov 2016 //
GLOBENEWSWIRE
Helsinn creates $50M VC fund to back early-stage cancer companies
11 Oct 2016 //
FIERCE BIOTECH
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development
08 Aug 2016 //
PR NEWSWIRE
San Diego`s MEI Pharma (MSHL) Bags Cancer Deal Worth $464 Million With Helsinn
08 Aug 2016 //
BIOSPACE
Helsinn Announces Top-Line Results of its Phase IIb Trial With Elsiglutide
04 May 2016 //
PR NEWS WIRE
Helsinn and Eisai Announce Revised U.S. Collaboration for CINV Franchise
18 Mar 2016 //
PR NEWS WIRE
Mundipharma gets exclusive rights to market & distribute Helsinn`s anamorelin
16 Feb 2016 //
PHARMABIZ
EMA to review Helsinn’s anamorelin HCI marketing authorisation application
30 Nov 2015 //
EUROPEAN PHARMACEUTICAL REVIEW
Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO in ASCO
13 Nov 2015 //
PR NEWS WIRE
Global Drugs Market 2015-2019 with GSK,Helsinn,Heron,Merck & Tesaro Dominating
04 Nov 2015 //
PR NEWS WIRE
Chugai Pharma launches netupitant-palonosetron fixed dose combo in UK
10 Sep 2015 //
PHARMABIZ
